Teva Announces Acquisition of Anda Inc.

JERUSALEM–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today
announced that it has entered into a definitive agreement to purchase
Allergan’s Anda Inc., the 4th largest distributor of generic
pharmaceuticals in the U.S. for $500 million.

“Anda is a natural fit into our business in general and our extensive
supply chain network in particular,” stated Siggi Olafsson, President &
CEO of Global Generic Medicines. “We believe Anda is truly a unique
company which further enhances the offerings that Teva can provide. This
strategic move enables us and our customers to improve capabilities and
flexibility given the changes the pharmaceutical industry is currently
undergoing, in order to provide access to more patients throughout the
country. Additionally, both Teva and Anda’s customers will benefit from
our ability as the largest producer of medicines in the world to
leverage our size and scale. »

“Joining Teva opens a new world of possibilities for Anda, especially as
the appropriate utilization of generic medicines remains the most
effective means by which to ensure broad patient access,” stated Charles
D. Phillips, President & CEO of Anda. “We look forward to the
opportunity to utilize the Teva network to the advantage of our
customers and patients across the country.”

Anda distributes generic, brand, specialty and over-the-counter
pharmaceutical products from more than 300 manufacturers to retail
independent and chain pharmacies, nursing homes, mail order pharmacies,
hospitals, clinics and physician offices across the United States.

For the full year 2016, Anda is expected to generate more than $1
billion in third-party net revenue.

As part of the deal, Teva will acquire three distribution centers in
Olive Branch, MS; Weston, FL; and Groveport, OH, with a total of over
650 employees.

Olafsson continued, “Anda will continue to operate as a stand-alone
business and report directly to me. The addition of Anda and their
ability to service over half of their 60,000 customers within 24 hours,
combined with our existing offerings, will allow us to provide even
better service to our customers.”

The closing of this transaction is subject to antitrust clearance and
satisfaction of other conditions. The transaction is expected to close
in the second half of 2016.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading
global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by millions of patients every
day. Headquartered in Israel, Teva is the world’s largest generic
medicines producer, leveraging its portfolio of more than 1,800
molecules to produce a wide range of generic products in nearly every
therapeutic area. In specialty medicines, Teva has a world-leading
position in innovative treatments for disorders of the central nervous
system, including pain, as well as a strong portfolio of respiratory
products. Teva integrates its generics and specialty capabilities in its
global research and development division to create new ways of
addressing unmet patient needs by combining drug development
capabilities with devices, services and technologies. Teva’s net
revenues in 2015 amounted to $19.7 billion. For more information, visit www.tevapharm.com.

Teva’s Safe Harbor Statement under the U. S. Private Securities
Litigation Reform Act of 1995:

This release contains forward-looking statements, which are based on
management’s current beliefs and expectations and involve a number of
known and unknown risks and uncertainties that could cause our future
results, performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products;
competition for our specialty products, especially Copaxone® (which
faces competition from orally-administered alternatives and a generic
version); our ability to integrate the acquisition of Allergan plc’s
worldwide generic pharmaceuticals business (“Actavis Generics”) and to
realize the anticipated benefits of such acquisition (and the timing of
realizing such benefits); the fact that following the consummation of
the Actavis Generics acquisition, we are dependent to a much larger
extent than previously on our generic pharmaceutical business; potential
restrictions on our ability to engage in additional transactions or
incur additional indebtedness as a result of the substantial amount of
debt we incurred to finance the Actavis Generics acquisition; the fact
that for a period of time following the consummation of the Actavis
Generics acquisition, we will have significantly less cash on hand than
previously, which could adversely affect our ability to grow; the
possibility of material fines, penalties and other sanctions and other
adverse consequences arising out of our ongoing FCPA investigations and
related matters; our ability to achieve expected results from
investments in our pipeline of specialty and other products; our ability
to identify and successfully bid for suitable acquisition targets or
licensing opportunities, or to consummate and integrate acquisitions;
the extent to which any manufacturing or quality control problems damage
our reputation for quality production and require costly remediation;
increased government scrutiny in both the U.S. and Europe of our patent
settlement agreements; our exposure to currency fluctuations and
restrictions as well as credit risks; the effectiveness of our patents,
confidentiality agreements and other measures to protect the
intellectual property rights of our specialty medicines; the effects of
reforms in healthcare regulation and pharmaceutical pricing,
reimbursement and coverage; competition for our generic products, both
from other pharmaceutical companies and as a result of increased
governmental pricing pressures; governmental investigations into sales
and marketing practices, particularly for our specialty pharmaceutical
products; adverse effects of political or economic instability, major
hostilities or acts of terrorism on our significant worldwide
operations; interruptions in our supply chain or problems with internal
or third-party information technology systems that adversely affect our
complex manufacturing processes; significant disruptions of our
information technology systems or breaches of our data security;
competition for our specialty pharmaceutical businesses from companies
with greater resources and capabilities; the impact of continuing
consolidation of our distributors and customers; decreased opportunities
to obtain U.S. market exclusivity for significant new generic products;
potential liability in the U.S., Europe and other markets for sales of
generic products prior to a final resolution of outstanding patent
litigation; our potential exposure to product liability claims that are
not covered by insurance; any failure to recruit or retain key
personnel, or to attract additional executive and managerial talent; any
failures to comply with complex Medicare and Medicaid reporting and
payment obligations; significant impairment charges relating to
intangible assets, goodwill and property, plant and equipment; the
effects of increased leverage and our resulting reliance on access to
the capital markets; potentially significant increases in tax
liabilities; the effect on our overall effective tax rate of the
termination or expiration of governmental programs or tax benefits, or
of a change in our business; variations in patent laws that may
adversely affect our ability to manufacture our products in the most
efficient manner; environmental risks; and other factors that are
discussed in our Annual Report on Form 20-F for the year ended December
31, 2015 and in our other filings with the U.S. Securities and Exchange
Commission (the « SEC »). Forward-looking statements speak only as of the
date on which they are made and we assume no obligation to update or
revise any forward-looking statements or other information, whether as a
result of new information, future events or otherwise.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160803005327/en/